Niurguyana Nikolaevna Grigorieva
Research Subjects
Niurguyana Nikolaevna Grigorieva has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Fedor Evgenievich Shadrichev
Pavlov First Saint Petersburg State Medical University
3 shared publications - Nyurguyana Grigoryeva
St. Petersburg Territorial Diabetological Center
2 shared publications - Svetlana N. Tultseva
Academician I.P. Pavlov First St. Petersburg State Medical University
2 shared publications - Vladimir A. Antonov
Academician I.P. Pavlov First St. Petersburg State Medical University
2 shared publications Elena Nikolaevna Stepanova
Санкт-Петербургский территориальный диабетологический центр
1 shared publication- Fatima O. Ushanova
Pirogov Russian National Research Medical University
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 5 (4) , 56-65
Interdisciplinary approach to the management of diabetic retinopathy: The role of ophthalmologist and endocrinologist
Diabetic retinopathy (DR) and diabetic macular edema (DME) are common chronic complications of diabetes mellitus, the fight against which is an urgent problem of modern healthcare. DR is the fifth most common cause of blindness worldwide and the main cause of vision loss in patients with diabetes. An interdisciplinary approach plays a key role in the effective management of DR, in which the role of the endocrinologist is to achieve optimal indicators of glycemic control as the main pathogenetic factor, and regular referral to screening of patients from risk groups. In turn, ophthalmologists are faced with the task of directly diagnosing changes in the fundus and treating eye diseases at various stages. Modern ideas about the mechanisms of development of DR and the role of VEGF allow us to identify several main areas of therapy. Thus, the main method of treating DR is laser retinal coagulation (LRC), and the most effective method of treating DME is considered to be a combination of LRC and intravitreal administration of angiogenesis inhibitors. Currently, intravitreal administration of agents that prevent the neoangiogenesis is the first-line treatment for DME involving the center of the macula. This review provides information on the pathogenesis, modern classification and current approaches to the management of patients with DR in the framework of the interaction of an ophthalmologist and an endocrinologist.
- 1 January 2024
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 5 (4) , 56-65
Open AccessInterdisciplinary approach to the management of diabetic retinopathy: The role of ophthalmologist and endocrinologist
Diabetic retinopathy (DR) and diabetic macular edema (DME) are common chronic complications of diabetes mellitus, the fight against which is an urgent problem of modern healthcare. DR is the fifth most common cause of blindness worldwide and the main cause of vision loss in patients with diabetes. An interdisciplinary approach plays a key role in the effective management of DR, in which the role of the endocrinologist is to achieve optimal indicators of glycemic control as the main pathogenetic factor, and regular referral to screening of patients from risk groups. In turn, ophthalmologists are faced with the task of directly diagnosing changes in the fundus and treating eye diseases at various stages. Modern ideas about the mechanisms of development of DR and the role of VEGF allow us to identify several main areas of therapy. Thus, the main method of treating DR is laser retinal coagulation (LRC), and the most effective method of treating DME is considered to be a combination of LRC and intravitreal administration of angiogenesis inhibitors. Currently, intravitreal administration of agents that prevent the neoangiogenesis is the first-line treatment for DME involving the center of the macula. This review provides information on the pathogenesis, modern classification and current approaches to the management of patients with DR in the framework of the interaction of an ophthalmologist and an endocrinologist.
- Open Access
- 14 July 2023
- Published by ECO-Vector LLC in Ophthalmology Reports
- Vol. 16 (2) , 49-61
The efficacy of local glucocorticosteroid therapy in nonarteritic anterior ischemic optic neuropathy
BACKGROUND: Non-arteritic anterior ischemic optic neuropathy is the second most common optic neuropathy after glaucoma. The effectiveness of the glucocorticosteroid therapy use for the non-arteritic anterior ischemic optic neuropathy treatment remains a subject of debate. Currently, the search for markers of the diseases therapeutic window is under way. AIM: The aim of this study is to evaluate the use of local glucocorticosteroid therapy as an emergency care for non-arteritic anterior ischemic optic neuropathy. MATERIALS AND METHODS: 41 patients with non-arteritic anterior ischemic optic neuropathy were enrolled in the study. To evaluate optic nerve head and macula morphometric characteristics, optical coherence tomography was performed, additionally, diameters of arteries and veins were assessed at 4 vascular arcades. Patients were divided into 2 groups according to the presence of intraretinal fluid. The first (main) group consisted of 23 patients with intraretinal fluid, in the second (control) group 18 patients without intraretinal fluid were included. The first group was further divided into two subgroups according to the medical aid recourse periods up to 5 days, and from 6 to 21 days (subgroup 1 9 patients, subgroup 2 14 patients). RESULTS: Correlations between the dynamics of optic nerve head edema changes and the caliber of arteries (negative correlation) and that of veins (positive correlation) were revealed. Sub-tenon injection of long-acting glucocorticosteroid did not lead to morpho-functional improvement in first group patients. Local short-acting glucocorticosteroid therapy accomplished in the acute period of the disease made it possible to achieve an improvement in best corrected visual acuity during the first month in group 1 patients without any further worsening of it. CONCLUSIONS: When providing emergency care to patients with non-arteritic anterior ischemic optic neuropathy during the first 5 days from the disease onset, the local use of glucocorticosteroid therapy is advisable.
- 14 July 2023
- Published by ECO-Vector LLC in Ophthalmology Reports
- Vol. 16 (2) , 49-61
Open AccessThe efficacy of local glucocorticosteroid therapy in nonarteritic anterior ischemic optic neuropathy
BACKGROUND: Non-arteritic anterior ischemic optic neuropathy is the second most common optic neuropathy after glaucoma. The effectiveness of the glucocorticosteroid therapy use for the non-arteritic anterior ischemic optic neuropathy treatment remains a subject of debate. Currently, the search for markers of the diseases therapeutic window is under way. AIM: The aim of this study is to evaluate the use of local glucocorticosteroid therapy as an emergency care for non-arteritic anterior ischemic optic neuropathy. MATERIALS AND METHODS: 41 patients with non-arteritic anterior ischemic optic neuropathy were enrolled in the study. To evaluate optic nerve head and macula morphometric characteristics, optical coherence tomography was performed, additionally, diameters of arteries and veins were assessed at 4 vascular arcades. Patients were divided into 2 groups according to the presence of intraretinal fluid. The first (main) group consisted of 23 patients with intraretinal fluid, in the second (control) group 18 patients without intraretinal fluid were included. The first group was further divided into two subgroups according to the medical aid recourse periods up to 5 days, and from 6 to 21 days (subgroup 1 9 patients, subgroup 2 14 patients). RESULTS: Correlations between the dynamics of optic nerve head edema changes and the caliber of arteries (negative correlation) and that of veins (positive correlation) were revealed. Sub-tenon injection of long-acting glucocorticosteroid did not lead to morpho-functional improvement in first group patients. Local short-acting glucocorticosteroid therapy accomplished in the acute period of the disease made it possible to achieve an improvement in best corrected visual acuity during the first month in group 1 patients without any further worsening of it. CONCLUSIONS: When providing emergency care to patients with non-arteritic anterior ischemic optic neuropathy during the first 5 days from the disease onset, the local use of glucocorticosteroid therapy is advisable.
- Open Access
- 30 September 2021
- Published by ECO-Vector LLC in Ophthalmology Reports
- Vol. 14 (2) , 105-115
COVID-19 as a new risk factor for the development of acute vascular diseases of the optic nerve and retina
The new coronavirus disease (COVID-19) is a viral respiratory infection accompanied by systemic endotheliitis. COVID-19 patients usually encounter changes related to hypercoagulability, hypofibrinolysis, and increased intravascular platelet aggregation. There is also a vascular wall thromboresistance decrease and impaired vasomotor function, which significantly increase the risk of thromboembolic complications. Currently, pathogenic aspects of the relationship between COVID-19 and vascular and inflammatory conditions of the optic nerve and retina are actively investigated. One of the triggers of impaired blood flow in ocular vessels may be a perfusion pressure decrease, observed in the acute period of the infectious process. This is related to both COVID-19 clinical course features and to resuscitation specificity as well. Secondary autoimmune inflammation is being considered as a mechanism of damage to the vascular wall in the post-infectious period. In this publication, possible pathogenic links of these diseases are considered for the first time in a specific context of the example of ischemic optic neuropathy associated with coronavirus infection.
- 30 September 2021
- Published by ECO-Vector LLC in Ophthalmology Reports
- Vol. 14 (2) , 105-115
Open AccessCOVID-19 as a new risk factor for the development of acute vascular diseases of the optic nerve and retina
The new coronavirus disease (COVID-19) is a viral respiratory infection accompanied by systemic endotheliitis. COVID-19 patients usually encounter changes related to hypercoagulability, hypofibrinolysis, and increased intravascular platelet aggregation. There is also a vascular wall thromboresistance decrease and impaired vasomotor function, which significantly increase the risk of thromboembolic complications. Currently, pathogenic aspects of the relationship between COVID-19 and vascular and inflammatory conditions of the optic nerve and retina are actively investigated. One of the triggers of impaired blood flow in ocular vessels may be a perfusion pressure decrease, observed in the acute period of the infectious process. This is related to both COVID-19 clinical course features and to resuscitation specificity as well. Secondary autoimmune inflammation is being considered as a mechanism of damage to the vascular wall in the post-infectious period. In this publication, possible pathogenic links of these diseases are considered for the first time in a specific context of the example of ischemic optic neuropathy associated with coronavirus infection.
- Open Access
- 15 March 2014
- Published by ECO-Vector LLC in Ophthalmology Reports
- Vol. 7 (1) , 28-33
“Hylabak” and “Theagel” use for dry eye syndrome in diabetic patients
During last ten years the prevalence of diabetes mellitus significantly increased. Taking into consideration the role of metabolic impairments in the pathogenesis of diabetes and of dry eye syndrome, the increase in number of patients suffering from kerato-conjunctival xerosis on the background of carbohydrate metabolism disorder is highly predictive. This is favored also by the fact that type 2 diabetes, assuring the main increase in disease incidence, is constantly “rejuvenating”, more and more covering a substantial group of a socially-active part of population, which assumes a modern life-style with all the adverse effects accompanying hasty urbanization. The article is dedicated to the comprehensive dry eye syndrome treatment in diabetic patients.
- 15 March 2014
- Published by ECO-Vector LLC in Ophthalmology Reports
- Vol. 7 (1) , 28-33
Open Access“Hylabak” and “Theagel” use for dry eye syndrome in diabetic patients
During last ten years the prevalence of diabetes mellitus significantly increased. Taking into consideration the role of metabolic impairments in the pathogenesis of diabetes and of dry eye syndrome, the increase in number of patients suffering from kerato-conjunctival xerosis on the background of carbohydrate metabolism disorder is highly predictive. This is favored also by the fact that type 2 diabetes, assuring the main increase in disease incidence, is constantly “rejuvenating”, more and more covering a substantial group of a socially-active part of population, which assumes a modern life-style with all the adverse effects accompanying hasty urbanization. The article is dedicated to the comprehensive dry eye syndrome treatment in diabetic patients.